Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H, Salminen S
Department of Pediatrics, the University of Turku, Turku, Finland.
Am J Clin Nutr. 2001 Feb;73(2 Suppl):444S-450S. doi: 10.1093/ajcn/73.2.444s.
The gastrointestinal tract functions as a barrier against antigens from microorganisms and food. The generation of immunophysiologic regulation in the gut depends on the establishment of indigenous microflora. This has led to the introduction of novel therapeutic interventions based on the consumption of cultures of beneficial live microorganisms that act as probiotics. Among the possible mechanisms of probiotic therapy is promotion of a nonimmunologic gut defense barrier, which includes the normalization of increased intestinal permeability and altered gut microecology. Another possible mechanism of probiotic therapy is improvement of the intestine's immunologic barrier, particularly through intestinal immunoglobulin A responses and alleviation of intestinal inflammatory responses, which produce a gut-stabilizing effect. Many probiotic effects are mediated through immune regulation, particularly through balance control of proinflammatory and anti-inflammatory cytokines. These data show that probiotics can be used as innovative tools to alleviate intestinal inflammation, normalize gut mucosal dysfunction, and down-regulate hypersensitivity reactions. More recent data show that differences exist in the immunomodulatory effects of candidate probiotic bacteria. Moreover, distinct regulatory effects have been detected in healthy subjects and in patients with inflammatory diseases. These results suggest that specific immunomodulatory properties of probiotic bacteria should be characterized when developing clinical applications for extended target populations.
胃肠道作为抵御微生物和食物抗原的屏障发挥作用。肠道免疫生理调节的产生依赖于本土微生物群的建立。这促使了基于食用作为益生菌的有益活微生物培养物的新型治疗干预措施的引入。益生菌治疗的可能机制之一是促进非免疫性肠道防御屏障,这包括使增加的肠道通透性和改变的肠道微生态正常化。益生菌治疗的另一个可能机制是改善肠道免疫屏障,特别是通过肠道免疫球蛋白A反应和减轻肠道炎症反应,从而产生肠道稳定作用。许多益生菌效应是通过免疫调节介导的,特别是通过促炎和抗炎细胞因子的平衡控制。这些数据表明,益生菌可作为缓解肠道炎症、使肠道黏膜功能障碍正常化以及下调超敏反应的创新工具。最新数据表明,候选益生菌的免疫调节作用存在差异。此外,在健康受试者和炎症性疾病患者中检测到了不同的调节作用。这些结果表明,在为更广泛的目标人群开发临床应用时,应表征益生菌的特定免疫调节特性。